Analytical Data
-
Gene name
MLANA
- Application
-
Alternative Names
Antigen LB39-AAAntigen SK29-AAProtein Melan-A
-
Species
Human
-
Source
E. coli
-
Tag
N- His-B2M
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16655
-
Expression Region
1-118aa
-
Molecular Weight
27.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MLANA, or Melanoma Antigen, is a protein that has gained attention in cancer research, particularly in the context of melanoma, a type of skin cancer. This protein is a part of the family of melanoma-associated antigens and is primarily expressed in melanoma cells, making it a potential target for immunotherapy. Research on MLANA has focused on understanding its role in tumor biology and the immune response against melanoma. The expression of MLANA is often associated with the development of immune responses in patients, particularly in those undergoing treatment with immune checkpoint inhibitors. Given the increasing incidence of melanoma and the limitations of existing treatment modalities, MLANA presents an interesting avenue for therapeutic development. By investigating the mechanisms of MLANA expression and its interactions with immune cells, researchers aim to leverage this knowledge to enhance the efficacy of immunotherapies and improve clinical outcomes for melanoma patients. Moreover, MLANA may provide insights into cancer immunogenicity and the development of personalized cancer vaccines. As the understanding of this protein deepens, it could pave the way for innovative approaches that harness the immune system to recognize and eradicate melanoma cells, ultimately contributing to more effective cancer treatment strategies.
